PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Sep 21, 2020

byprotokinetixp

Seeking improved treatments for dry eye disease

A 2017 study from the American Optometric Association found that more than 16 million Americans are affected by dry eye disease (DED), also known as dry eye syndrome (DES), including...Read more

Aug 21, 2020

byprotokinetixp

Invest in the potential of AAGP® for type-1 diabetes

While there is currently no cure for diabetes, we believe our anti-aging glycopeptide, AAGP®, may be the essential link to the successful treatments of tomorrow. In preliminary testing, AAGP® has been...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.